Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The observations are of procedural in nature and will be responded to within the stipulated time
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
The net-zero target approval complements the company's near-term emission reduction targets
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Developed in consultation with clinicians and patients for an enhanced user experience
India has taken the lead in recognising NAFLD as a major non-communicable disease
Subscribe To Our Newsletter & Stay Updated
